Drug intelligence / Profile preview

jacaranone

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

Jacaranone is a naturally occurring small molecule classified as a bicyclic sesquiterpene phytoquinoid, originally isolated from plants such as Senecio scandens, Ternstroemia japonica, and Jacaranda copaia. Its chemical structure features a cyclohexadiene ring with hydroxyl, keto, and methyl acetic acid ester groups, with a molecular formula of C9H10O4 and molecular weight 182.17 g/mol. Jacaranone exhibits a range of biological activities, most notably **antitumor and antiproliferative properties**. Mechanistically, it induces apoptosis in tumor cells (including melanoma, breast, ovarian, prostate carcinoma, liver, and leukemia cell lines) through modulation of the TNFR1 (Tumor Necrosis Factor Receptor 1) pathway. It degrades the inhibitor of apoptosis protein cIAP-2 (E3 ubiquitin ligase), leading to increased cell death by promoting the formation of the TNFR1 complex II, thus favoring apoptotic over survival signaling. Jacaranone also increases ROS (reactive oxygen species) production, Akt inactivation, and p38 MAPK phosphorylation, leading to increased proapoptotic protein Bax. It has shown significant antitumor activity in preclinical xenotransplantation and murine tumor models, with selective toxicity toward malignant cells and minimal toxicity in normal cells[1][3][4][5][7].

Other names
methyl 2-(1-hydroxy-4-oxocyclohexa-2,5-dien-1-yl)acetatejacaramome2,5-cyclohexadiene-1-acetic acid, 1-hydroxy-4-oxo-, methyl ester
02

Targets

NADH:ubiquinone oxidoreductase subunit familyBIRC3 (Baculoviral IAP repeat-containing protein 3)RK (Ribokinase)AKT (RAC-alpha serine/threonine-protein kinase)

Beyond the preview

Go deeper on jacaranone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on jacaranone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call